Celldex Therapeutics’ anti-KIT antibody hit the primary endpoint in a mid-stage test in chronic spontaneous urticaria, with some analysts describing the data as better than a Novartis therapy that’s further ahead in development.
Celldex’s Phase II trial set three doses of barzolvolimab against placebo in 208 patients with chronic spontaneous urticaria (CSU) who were symptomatic despite antihistamine treatment, including some who were refractory to biologics such as Novartis and Genentech’s Xolair. There are currently no approved treatments for patients whose disease is not controlled by Xolair.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.